Physiometrix (NASDAQ:PHYX)
Historical Stock Chart
From Jun 2019 to Jun 2024
Physiometrix, Inc. Discloses Nasdaq Listing Deficiency
NO. BILLERICA, Mass., May 25 /PRNewswire/ -- Physiometrix, Inc. (NASDAQ: PHYX)
announced today that the company received a letter from Nasdaq on April 5,
2005, which cited the company's non-compliance with the requirement that the
company maintain either shareholder equity of a minimum of $2,500,000 or
$35,000,000 in listed securities or $500,000 of net income from continuing
operations for two of the last three fiscal years, as required in marketplace
rule 4310(c) (2)(B). Under these circumstances, the Nasdaq staff has reviewed
the company's eligibility for continued listing. The company provided a plan of
compliance to Nasdaq on April 20, 2005 to achieve and maintain compliance with
all the Nasdaq Smallcap listing requirements.
After review of this plan, Nasdaq has notified the company on May 18, 2005 that
the plan submitted did not provide a definitive plan evidencing its ability to
achieve near term compliance with the continued listing requirements or
maintain such compliance over an extended period of time. Nasdaq therefore
advised the company that, its securities are subject to delisting and will be
delisted on May 27, 2005 unless the company requests an appeal and a hearing
before the Nasdaq Listing Qualifications Panel. This will delay any delisting
until the hearing date, which will be within 45 days of the date the company
requests the hearing.
The company filed the request for a hearing on May 23, 2005 and intends to
continue activities designed to achieve compliance with the continued listing
requirements in time to avoid delisting.
Physiometrix Inc. designs, manufactures and markets noninvasive medical
products -- based on novel gel materials, sophisticated signal-processing
electronics technologies, and proprietary software -- for use in anesthesia-
monitoring during surgical procedures. For more information, please visit the
Company's Web site at http://www.physiometrix.com/.
Statements in this press release regarding Physiometrix's growth and future
business results of the Company are "forward-looking" statements as defined in
the Private Securities Litigation Reform Act of 1995. Such statements are
based upon management's current expectations and are subject to a number of
factors and uncertainties. Information contained in these forward-looking
statements is inherently uncertain, and actual performance and results may
differ materially due to many important factors. Such factors that could cause
actual results to differ materially from any forward-looking statements made by
the Company include, among others, revenue estimates, dependence on existing
and future products, dependence upon third-party distribution and sales
arrangements, the existence of alternative technologies and the potential
emergence of new methods for consciousness monitoring, uncertainty of market
acceptance, intense competition, partnership agreements, and government
regulations, especially regulatory approvals. These and other relevant risks
are described in the Company's Form 10-K dated March 31, 2005 filed with the
SEC. The Company disclaims any obligation to update information contained in
any forward-looking statement to reflect events or circumstances occurring
after the date of this press release.
CONTACT:
Daniel W. Muehl, CFO
Physiometrix Inc.
978-670-2422
DATASOURCE: Physiometrix, Inc.
CONTACT: Daniel W. Muehl, CFO of Physiometrix Inc., +1-978-670-2422
Web site: http://physiometrix.com/